Key result
AT1a and AT1b receptor deficiency or losartan treatment did not alter morphological or molecular alterations in a mouse model of cerulein-induced chronic pancreatitis.
Why the study?
Does AT1a and AT1b receptor deficiency or losartan treatment prevent the development of cerulein-induced chronic pancreatitis in mice?
Does AT1a and AT1b receptor deficiency or losartan treatment prevent the development of cerulein-induced chronic pancreatitis in mice?
AT1a and AT1b receptor pathways do not appear essential for the development of cerulein-induced chronic pancreatitis in mice, suggesting RAS blockade may not prevent pancreatitis in this specific model.
Answers are grounded in this paper and cite their sources.
Does not support RAS blockade for chronic pancreatitis prevention; leaves open roles in other models or human disease.
The intraorgan renin-angiotensin system (RAS) plays an important role in the pathophysiology of a variety of diseases and has been implicated in fibrogenesis. The role of RAS in the development of chronic pancreatitis is not well established. The blockade of RAS in rat models with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor 1 (AT1) blockers (ARBs) mostly have reduced pancreatic inflammation and fibrosis with a few exceptions. At the same time, the use of ACEi and ARBs in humans is associated with a modest risk of acute pancreatitis. The aim of this study was to elucidate the effect of the AT1 signaling pathway in the development of pancreatitis using AT1a- and AT1b-deficient mice as well as the ARB losartan. Chronic pancreatitis was induced by repetitive cerulein administration in C57BL/6J wild-type (WT) and AT1a- and AT1b-deficient mice (AT1a-/- and AT1b-/-), and pancreatic injury was assessed at day 10. Pancreatic weight of cerulein treated groups was significantly reduced. There was severe parenchymal atrophy and fibrosis assessed by histological examination. Fibrosis was accompanied by activation of pancreatic stellate cells (PSC) evaluated by Western blot analysis for alpha-smooth muscle actin. No differences were seen between cerulein-treated WT, AT1a-/- , AT1b-/- mice, or losartan treated-WT mice with regards to morphological or molecular alterations induced by cerulein. Our results demonstrate that AT1a and AT1b receptor pathways do not seem to be essential for the development of pancreatitis in the mouse model of pancreatitis induced by repetitive cerulein injury.
No takes yet. Share an insight, caveat, or question.
Ulmasov et al. (2010) studied Cerulein-induced chronic pancreatitis. AT1a and AT1b deficiency or losartan vs. Wild-type (WT) mice was evaluated on Morphological or molecular alterations (pancreatic injury). AT1a and AT1b receptor deficiency or losartan treatment did not alter morphological or molecular alterations in a mouse model of cerulein-induced chronic pancreatitis.
Synapse has enriched 10 related papers. Consider them for comparative context: